- Home
- TLSI vs SCPH Comparison
TLSI vs SCPH Comparison
Compare TLSI & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- SCPH
- Stock Information
- Founded
- TLSI 2010
- SCPH 2013
- Country
- TLSI United States
- SCPH United States
- Employees
- TLSI N/A
- SCPH N/A
- Industry
- TLSI Medical Specialities
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- SCPH Health Care
- Exchange
- TLSI Nasdaq
- SCPH Nasdaq
- Market Cap
- TLSI 204.0M
- SCPH 173.6M
- IPO Year
- TLSI N/A
- SCPH 2017
- Fundamental
- Price
- TLSI $5.54
- SCPH $3.84
- Analyst Decision
- TLSI Strong Buy
- SCPH Strong Buy
- Analyst Count
- TLSI 5
- SCPH 3
- Target Price
- TLSI $10.90
- SCPH $14.00
- AVG Volume (30 Days)
- TLSI 39.7K
- SCPH 289.6K
- Earning Date
- TLSI 08-13-2025
- SCPH 08-13-2025
- Dividend Yield
- TLSI N/A
- SCPH N/A
- EPS Growth
- TLSI N/A
- SCPH N/A
- EPS
- TLSI N/A
- SCPH N/A
- Revenue
- TLSI $32,141,000.00
- SCPH $41,982,000.00
- Revenue This Year
- TLSI $55.52
- SCPH $108.95
- Revenue Next Year
- TLSI $54.76
- SCPH $73.83
- P/E Ratio
- TLSI N/A
- SCPH N/A
- Revenue Growth
- TLSI 46.20
- SCPH 138.10
- 52 Week Low
- TLSI $3.50
- SCPH $1.94
- 52 Week High
- TLSI $6.08
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- TLSI 53.07
- SCPH 56.83
- Support Level
- TLSI $5.18
- SCPH $3.86
- Resistance Level
- TLSI $5.54
- SCPH $4.17
- Average True Range (ATR)
- TLSI 0.32
- SCPH 0.23
- MACD
- TLSI 0.01
- SCPH -0.06
- Stochastic Oscillator
- TLSI 82.81
- SCPH 33.33
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.